Our recent studies have shown that PTPN2 deletion sensitizes otherwise therapy-resistant AT3 mammary tumors to PD-1 blockade10 whereas in this study we have shown that Compound 182 can increase TILs and repress AT3 tumor growth (Fig. 4d–f). Here, PTPN2 is linked to neoplasm.